Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prenatal Betamethasone not Linked to Adverse Neurocognitive Problems

Key clinical point: Prenatal betamethasone administration is not associated with adverse neurocognitive effects in midchildhood.

Major finding: Rates of disability-free survival and survival with moderate to severe disability were similar for children with and without fetal growth restriction, whether exposed prenatally to betamethasone or placebo.

Study details: The findings are based on a preplanned secondary analysis of a placebo-controlled, randomized clinical trial involving 988 Australian and New Zealander children tracked through age 6-8 years following births between April 1998 and July 2004.

Disclosures: The research was funded by the National Health Medical Research Council of Australia, the Health Research Council of New Zealand and the Auckland Medical Research Foundation. One coauthor reported receiving grants from National Health and Medical Research Council of Australia, and a second coauthor received grants from the Auckland Medical Research Foundation.

Citation:

Cartwright RD et al. JAMA Netw Open. 2019 Feb 1. doi:10.1001/jamanetworkopen.2018.7636.